A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
Fiche publication
Date publication
février 2023
Journal
Clinical kidney journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, Małyszko J, Ruilope LM, Rossignol P, Rossing P, Pecoits-Filho R, Anker SD, Joseph A, Lawatscheck R, Wilson D, Gebel M, Bakris GL
Lien Pubmed
Résumé
Mineralocorticoid receptor antagonists (MRAs) reduce systolic blood pressure (SBP) and increase serum potassium concentration ([K]). This indirect comparison investigated any differences in SBP-lowering and hyperkalemia risk between finerenone, a nonsteroidal MRA, and the steroidal MRA spironolactone ± a potassium binder.
Mots clés
finerenone, hyperkalemia, hypertension, patiromer, spironolactone
Référence
Clin Kidney J. 2023 02;16(2):293-302